A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
Advanced Solid Tumors
DRUG: BMS-986360|DRUG: Docetaxel|DRUG: Nivolumab|DRUG: Capecitabine
Number of participants with Adverse Events (AEs), Up to approximately 2 years|Number of participants with Serious Adverse Events (SAEs), Up to approximately 2 years|Number of participants with Dose-Limiting Toxicities (DLTs), Up to approximately 2 years|Number of participants with AEs leading to discontinuation, Up to approximately 2 years|Number of deaths, Up to approximately 2 years
Maximum observed plasma concentration (Cmax), Up to approximately 2 years|Time of maximum observed plasma concentration (Tmax), Up to approximately 2 years|Area under the plasma concentration-time curve (AUC), Up to approximately 2 years|Part 1: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) by investigator, Up to approximately 2 years|Part 2: ORR based on RECIST v1.1 by blinded independent central review (BICR) assessment, Up to approximately 2 years|Part 1: Duration of Response (DOR) based on RECIST v1.1 by investigator, Up to approximately 2 years|Part 2: DOR based on RECIST v1.1 by BICR assessment, Up to approximately 2 years
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.